176 related articles for article (PubMed ID: 8722242)
1. [Cost analysis of treating depression. Comparison of tricyclic antidepressants and selective serotonine re-uptake inhibitors].
Mazurek J; Kiejna A
Psychiatr Pol; 1996; 30(1):87-98. PubMed ID: 8722242
[TBL] [Abstract][Full Text] [Related]
2. SSRIs vs tricyclic antidepressants.
Griffin GH
J Fam Pract; 1996 Feb; 42(2):110. PubMed ID: 8606296
[No Abstract] [Full Text] [Related]
3. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
[TBL] [Abstract][Full Text] [Related]
4. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the efficacy of traditional antidepressive agents and the new generation of antidepressives in the treatment of depressive disorders].
Cvjetković-Bosnjak M; Knezević A; Soldatović-Stajić B
Med Pregl; 1999; 52(3-5):108-11. PubMed ID: 10518394
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
Berndt ER; Bhattacharjya A; Mishol DN; Arcelus A; Lasky T
J Ment Health Policy Econ; 2002 Mar; 5(1):3-19. PubMed ID: 12529566
[TBL] [Abstract][Full Text] [Related]
7. TCAs or SSRIs as initial therapy for depression?
Tyra JM; Greenawald MH
J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
[No Abstract] [Full Text] [Related]
8. Effects of antidepressant treatments on health service utilization and medical costs among patients with depression: a nationwide population-based retrospective cohort study in Taiwan.
Su KP; Tang CH; Chang HC; Chiu WC; Lu N; Huang KC
Int Clin Psychopharmacol; 2019 Jul; 34(4):170-178. PubMed ID: 30964763
[TBL] [Abstract][Full Text] [Related]
9. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.
Anderson IM; Tomenson BM
BMJ; 1995 Jun; 310(6992):1433-8. PubMed ID: 7613276
[TBL] [Abstract][Full Text] [Related]
10. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
Laux G
Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
13. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
15. Long term pharmacotherapy of depression. Tricyclic antidepressants should not be first line treatment.
Gamble D; Thakore J
BMJ; 1998 Oct; 317(7166):1157; author reply 1158. PubMed ID: 9784471
[No Abstract] [Full Text] [Related]
16. Are SSRIs a cost-effective alternative to tricyclics?
Hotopf M; Lewis G; Normand C
Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
[TBL] [Abstract][Full Text] [Related]
17. Influences on cost effectiveness.
Patel V
Br J Psychiatry; 1996 Sep; 169(3):381. PubMed ID: 8879730
[No Abstract] [Full Text] [Related]
18. Antidepressant use among elderly patients.
Flint A; Silveira J
Am J Psychiatry; 2001 Feb; 158(2):328-30. PubMed ID: 11156834
[No Abstract] [Full Text] [Related]
19. One foot on the bandwagon?
Pies R
J Clin Psychopharmacol; 1995 Oct; 15(5):303-5. PubMed ID: 8830060
[No Abstract] [Full Text] [Related]
20. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.
Freemantle N; House A; Song F; Mason JM; Sheldon TA
BMJ; 1994 Jul; 309(6949):249-53. PubMed ID: 7832842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
